Trial watch: chemotherapy-induced immunogenic cell death in oncology
Immunogenic cell death (ICD) refers to an immunologically distinct process of regulated cell
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
death that activates, rather than suppresses, innate and adaptive immune responses. Such …
The cell stress and immunity cycle in cancer: toward next generation of cancer immunotherapy
The cellular stress and immunity cycle is a cornerstone of organismal homeostasis. Stress
activates intracellular and intercellular communications within a tissue or organ to initiate …
activates intracellular and intercellular communications within a tissue or organ to initiate …
Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer
DM Borràs, S Verbandt, M Ausserhofer, G Sturm, J Lim… - Cell Discovery, 2023 - nature.com
CD8+ T cell activation via immune checkpoint blockade (ICB) is successful in microsatellite
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …
instable (MSI) colorectal cancer (CRC) patients. By comparison, the success of …
The dynamic interface of genetics and immunity: toward future horizons in health & disease
AD Garg - Genes & Immunity, 2023 - nature.com
Understanding the genetic basis of immunological processes and their overall dynamics
under the influence of population immunogenetics and host-microbe interactions has been …
under the influence of population immunogenetics and host-microbe interactions has been …
The effector program of human CD8 T cells supports tissue remodeling
M Delacher, L Schmidleithner, M Simon… - Journal of Experimental …, 2024 - rupress.org
CD8 T lymphocytes are classically viewed as cytotoxic T cells. Whether human CD8 T cells
can, in parallel, induce a tissue regeneration program is poorly understood. Here, antigen …
can, in parallel, induce a tissue regeneration program is poorly understood. Here, antigen …
Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Current immunotherapies provide limited benefits against T cell-depleted tumors, calling for
therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a …
therapeutic innovation. Using multi-omics integration of cancer patient data, we predict a …
Neoadjuvant immunotherapy for patients with dMMR/MSI-high gastrointestinal cancers: a changing paradigm
Simple Summary Immune checkpoint inhibitors (ICIs) have transformed the treatment of
mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) colorectal cancers …
mismatch repair-deficient (MMR-D)/microsatellite instability-high (MSI-H) colorectal cancers …
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
An important challenge in the real-world management of patients with advanced clear-cell
renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint …
renal cell carcinoma (aRCC) is determining who might benefit from immune checkpoint …
Reverse translation: the key to increasing the clinical success of immunotherapy?
Therapeutic testing in animal models has been the cornerstone of translational medicine.
However, this trend is starting to change in favour of non-animal alternatives. Considering …
However, this trend is starting to change in favour of non-animal alternatives. Considering …
Targeting conserved TIM3+VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy
Despite the success of immunotherapy, overcoming immunoresistance in cancer remains
challenging. We identified a unique niche of tumor-associated macrophages (TAMs) …
challenging. We identified a unique niche of tumor-associated macrophages (TAMs) …